Q32 Bio INC

Q32 Bio Inc. announced the pricing of its public offering of common stock and pre-funded warrants, expecting to raise approximately $187.6 million.

Q32 Bio announced topline results from its Phase 2a trial of bempikibart for alopecia areata, showing robust clinical activity and a favorable safety profile.

Q32 Bio announced positive 36-week topline results from Part B of its SIGNAL-AA clinical trial for bempikibart in alopecia areata, showing a 35.3% mean reduction in SALT score.

Q32 Bio Inc. held its Annual Meeting of Stockholders on June 12, 2026, where shareholders elected directors, ratified the appointment of auditors, and approved executive compensation.

Q32 Bio Inc. announced a $55 million private placement of common stock and pre-funded warrants to accredited investors, aiming to advance clinical trials and support general corporate purposes.

Q32 Bio announced its first-quarter 2026 financial results, highlighting progress in its Phase 2a trial for bempikibart and a strengthened financial position.

Q32 Bio Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $7.6 million and strategic updates including the sale of ADX-097 assets and continued development of bempikibart.

Q32 Bio Inc. reported reduced net losses and extended its cash runway into 2027, while resolving a Nasdaq listing compliance issue and advancing its lead drug, bempikibart, with Fast Track designation.

Q32 Bio Inc. reported a net loss of $9.5 million for Q2 2025, narrowing its strategic focus to bempikibart for alopecia areata and discontinuing the ADX-097 program.

Q32 Bio Inc. reports a net loss of $11.0 million for Q1 2025, focusing on the advancement of bempikibart and evaluating strategic options for its complement inhibitor platform.

Q32 Bio Inc. reports a net loss of $17.6 million for the third quarter of 2024, alongside updates on clinical trials and financial activities.

Q32 Bio Inc. reports its second quarter 2024 financial results, highlighting a net loss of $15.9 million and progress in clinical trials for its lead product candidates.

Q32 Bio Inc. announces its 2024 financial results, highlighting progress in clinical trials and a strategic refocus on bempikibart for alopecia areata.

Q32 Bio Inc. finalizes its merger with Homology Medicines, Inc., detailing changes in capital stock, board composition, and executive compensation.

Homology Medicines has ceased development of its programs and reduced its workforce by 86% while pursuing strategic alternatives, including a merger with Q32 Bio.

Arthur Tzianabos, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Sven Ante Lundberg, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Kathleen Laporte, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Mark T Iwicki, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Diyong Xu, a Director and 10% owner of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Isaac Manke, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Q32 Bio Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 12, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

Q32 Bio Inc. announces its 2025 Annual Meeting to be held on June 13, 2025, featuring proposals including the election of directors, amendments to the certificate of incorporation, and ratification of the company's accounting firm.

Q32 Bio Inc. is holding its 2025 Annual Meeting of Stockholders online on June 13, 2025, to vote on key proposals including director elections, an amendment to limit officer liability, and ratification of the company's accounting firm.

Q32 Bio Inc. is registering for resale up to 1,682,045 shares of its common stock by selling stockholders after completing its merger with Homology Medicines.

OrbiMed Advisors LLC and affiliated entities have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Q32 Bio Inc. common stock due to an increase in outstanding shares.

OrbiMed Advisors and affiliates have increased their beneficial ownership in Q32 Bio Inc. to 17.4% following a recent private placement.

Atlas Venture entities acquired 625,000 shares of Q32 Bio Inc. in a private placement, bringing their total beneficial ownership to 11.5%.

OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed an amendment to their Schedule 13D reporting a change in beneficial ownership percentage in Q32 Bio Inc.

OrbiMed Advisors and OrbiMed Capital GP VII LLC filed an amended Schedule 13D, reporting a decrease in their beneficial ownership of Q32 Bio Inc. common stock to 15.4% due to an increase in the issuer's outstanding shares.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, disclosing a beneficial ownership of 5.49% in Q32 Bio Inc.

Boxer Capital Management, LLC and affiliated entities have reported beneficial ownership of 13.3% of Q32 Bio Inc.'s common stock as of June 30, 2026.

The Carlyle Group and its affiliates have reported beneficial ownership of 4.1% of Q32 Bio Inc.'s common stock as of June 18, 2026.

Biotechnology Value Fund and affiliates have reported a 9.99% beneficial ownership stake in Q32 Bio Inc. following recent equity transactions.

RA Capital Management and its affiliates have reported a 9.8% beneficial ownership stake in Q32 Bio Inc. following a recent private placement.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Q32 Bio Inc.'s common stock, primarily through exercisable warrants.